Trusted Long-Term Partners That Sponsors Can Depend On

PolyPid Ltd. is a Phase 3 biopharma company aiming to improve surgical outcomes through locally administered, controlled, extended-release therapeutics. PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with medications, enabling precise delivery of drugs at effective release rates, over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX₁₀₀ is in Phase 3 clinical trials for the prevention of sternal and abdominal surgical site infections (SSIs).

PolyPid’s Phase 3 clinical trial was designed as a multi-national and multi-center study. As such, PolyPid was in need of trusted partners and the most advanced Good Clinical Practice approved technology to ensure efficient design and execution of data strategies, as well as guaranteed data accuracy and integrity.